查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1999447

糖尿病相关眼科治疗市场：依治疗方法、给药途径、患者类型及最终用户划分－2026-2032年全球市场预测

Diabetes Associated Ophthalmic Treatment Market by Treatment Type, Route Of Administration, Patient Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，糖尿病相关眼科治疗市场价值将达到 67.4 亿美元，到 2026 年将成长至 73.6 亿美元，到 2032 年将达到 132.3 亿美元，复合年增长率为 10.09%。

主要市场统计数据
基准年 2025 67.4亿美元
预计年份：2026年 73.6亿美元
预测年份 2032 132.3亿美元
复合年增长率 (%) 10.09%

简要概述影响糖尿病相关眼科治疗和医疗保健服务模式的临床复杂性和策略考量。

糖尿病相关眼科疾病在临床和商业性都面临着复杂的挑战，涉及慢性病管理、先进的生物製药疗法以及不断发展的医疗服务模式。本报告整合了糖尿病患者眼科治疗的临床过程、新治疗方法以及相关人员，旨在整体情况。其目标是提供清晰、以医疗保健为导向的指南，将科学进展与治疗方法引入、获取和患者预后等方面的实际考虑联繫起来。

治疗创新、精准诊断和医疗保健服务体系的重新设计如何共同重新定义糖尿病眼科疾病的治疗路径和运作模式。

糖尿病眼科疾病的眼科治疗正经历一场变革，这场变革的驱动力来自治疗创新、数位医疗的融合以及不断发展的给药平台。过去几年，针对血管内皮生长因子 (VEGF) 及其相关路径的生物製药重新定义了标准治疗方案，而长效製剂和植入式给药系统则为治疗的连续性和临床工作流程引入了新的模式。因此，临床医生能够更有效地平衡疗效与减少就诊次数之间的关係，这反过来又改变了临床资源的分配方式以及病患监测的优先顺序。

了解 2025 年关税措施对供应链和眼科护理取得的连锁营运、采购和策略影响。

2025年起对部分进口药品、医疗设备及相关组件征收关税，将对眼科医疗保健产业的整个供应链、采购惯例和定价策略产生累积影响。生物製药、植入式给药系统和专用医疗设备的采购週期将受到直接衝击。到岸成本的增加将迫使医疗系统和付款方重新评估其采购方案。这将导致高需求治疗方法的短期供应中断，同时，製造商将更有奖励加快区域生产并调整供应路线，以减轻关税的影响。

综合細項分析揭示了治疗方法、给药途径、患者人口统计特征和医疗保健环境如何共同决定临床和商业性路径。

详细的細項分析揭示了治疗方法、给药途径、患者人口统计特征和医疗环境如何相互作用并影响临床实践和商业策略。就治疗方法类型而言，抗VEGF疗法仍然是临床管理的核心，阿柏西普、Bevacizumab、布罗卢西珠单抗、法利西单抗和雷珠单抗等药物各自具有不同的疗效、给药间隔和安全性，有助于治疗方法的选择。对于患有发炎性水肿或对抗VEGF疗法反应不佳的患者，皮质类固醇（如地塞米松植入剂、氟轻鬆植入剂和曲安奈德）是重要的替代疗法，其缓释特性可以改变监测频率并提高临床效率。雷射疗法，例如聚焦/网格状光凝固术和全视网膜光凝术，在某些疾病阶段继续发挥作用，作为药物治疗的补充。

区域间在基础设施、管理体制和准入优先事项方面的差异，对糖尿病眼科疾病治疗方法的引入途径产生了决定性的影响。

区域特征显着影响糖尿病相关眼科治疗方法的研发、推广和报销，三大主要区域各有不同的驱动因素。在美洲，先进的临床基础设施、强大的眼科专家网路和相对完善的支付机制支援新型生物製药和缓释植入的快速应用。然而，都市区之间的医疗服务可近性仍然存在差距，综合医疗网络和采购联盟的采购趋势也会影响处方药清单和治疗方法的可近性。

临床创新、生产规模和数位诊断的策略能力如何决定眼科治疗领域相关人员之间的竞争地位？

在眼科治疗生态系统中运作的产业相关人员，其临床创新、可扩展生产和稳健的商业性可行性整合能力日益凸显，从而形成差异化竞争格局。专注于生物製剂和长效药物的领先製药和生物技术开发公司，正大力投资于临床开发项目和真实世界数据（REW）收集，以证明其疗效的持续性并确立高端市场地位。同时，缓释植入和手术器械的製造商则致力于提高给药可靠性并减轻医疗机构的负担，这推动了高流量手术中心和专科诊所对这些产品的采用。

为相关人员提供实用策略指南，以协调糖尿病眼科疾病管理中的临床创新、供应弹性和支付方合作。

产业领导企业应采取多管齐下的策略，兼顾临床价值、供应韧性和与支付方的合作，以维持成长并改善患者疗效。首先，持续投资于差异化治疗方案，例如新型分子标靶、缓释製剂或可减少就诊次数的给药系统，将有助于提高其在临床实践中的应用，并满足真实临床环境中尚未满足的需求。同时，增加对严谨证据的投入，包括进行可操作性研究和建立註册登记系统，对于证明疗效的相对可比性以及推动医保报销方面的讨论至关重要。

严谨的混合方法研究框架，结合专家访谈、临床文献整合和透过三角测量进行资料检验，以支持实务见解。

本研究采用混合方法，将主要质性研究结果与全面的二手资料检验，以得出可靠且可操作的结论。主要研究包括对临床意见领袖、医院采购负责人、专科诊所管理人员和保险公司代表进行结构化访谈，以了解实际运作、处方决定因素和就医障碍。这些相关人员访谈用于将临床试验证据置于具体情境中，并检验关于医疗服务动态和物流限制的假设。

一份简明扼要、全面全面的分析报告，重点阐述了临床进步、供应韧性和相关人员合作将如何决定糖尿病眼科疾病护理的未来可及性和结果。

总而言之，糖尿病相关眼科疾病的管理正进入一个更精细、以能力主导的阶段，治疗方法、诊断准确性和交付模式的融合将重塑诊疗路径。价值链上的相关人员面临着如何将产品差异化与营运可行性、支付方期望以及以患者为中心的服务模式相协调的挑战。随着新型生物製药、缓释技术和数位诊断技术的日益成熟，成功的关键在于展现其在真实世界中的临床获益，同时确保供应链的稳健性和公平的获取途径。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依治疗方法分類的糖尿病相关眼科治疗市场

  • 抗 VEGF
    • 阿柏西普
    • Bevacizumab
    • 布罗卢西珠单抗
    • 法利西单抗
    • 雷尼珠单抗
  • 皮质类固醇
    • 地塞米松植入剂
    • 氟轻鬆植入物
    • 曲安奈德
  • 雷射治疗
    • 局部/网格光凝
    • 全视网膜光凝固术
  • 手术介入

第九章：糖尿病相关眼科治疗市场：依给药途径划分

  • 玻璃体内注射
    • 预填充式注射器
    • 管瓶
  • 全身给药
    • 静脉
    • 口服
  • 局部的
    • 眼药水
    • 软膏

第十章：依病患类型分類的糖尿病相关眼科治疗市场

  • 1型糖尿病
  • 2型糖尿病

第十一章：糖尿病相关眼科治疗市场：依最终使用者划分

  • 门诊手术中心
  • 医院
  • 眼科诊所
  • 零售药房

第十二章：糖尿病相关眼科治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：糖尿病相关眼科治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 糖尿病相关眼科治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国糖尿病相关眼科治疗市场

第十六章：中国糖尿病相关眼科治疗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Adverum Biotechnologies, Inc.
  • Aerpio Therapeutics, Inc.
  • Alimera Sciences, Inc.
  • Apexian Pharmaceuticals, Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Glycadia Pharmaceuticals, Inc.
  • Kodiak Sciences Inc.
  • Kubota Vision, Inc.
  • MingSight Pharmaceuticals, Inc.
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • Oxurion NV
  • Regeneron Pharmaceuticals, Inc.
  • Regenxbio Inc.
  • RemeGen Co., Ltd.
  • Santen Pharmaceutical Co., Ltd.
Product Code: MRR-563BF1FCF469

The Diabetes Associated Ophthalmic Treatment Market was valued at USD 6.74 billion in 2025 and is projected to grow to USD 7.36 billion in 2026, with a CAGR of 10.09%, reaching USD 13.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.74 billion
Estimated Year [2026] USD 7.36 billion
Forecast Year [2032] USD 13.23 billion
CAGR (%) 10.09%

A concise orientation to the clinical complexity and strategic considerations shaping diabetes-related ophthalmic therapies and care delivery models

Diabetes-associated eye disease presents a complex clinical and commercial challenge that intersects chronic disease management, advanced biologic therapies, and evolving care delivery models. This report introduces the therapeutic landscape by synthesizing clinical trajectories, emerging treatment modalities, and stakeholder priorities that shape how ophthalmic care for people with diabetes is delivered. The objective is to provide a clear, practitioner-focused orientation that links scientific advancement with practical considerations for therapy adoption, access, and patient outcomes.

Beginning with the clinical context, the narrative emphasizes how retinal vascular pathology, macular edema, and proliferative retinopathy drive vision impairment in both type 1 and type 2 diabetes populations. Treatment paradigms have shifted from primarily destructive laser approaches to pharmacologic modulation of pathogenic pathways, requiring new competencies among ophthalmology teams and novel supply chain arrangements for biologics and implantable devices. Consequently, clinicians, payers, and manufacturers must navigate a landscape where efficacy, safety, administration convenience, and total cost of care are balanced simultaneously.

The introduction frames subsequent sections by highlighting the interplay between technological innovation, regulatory strategy, and evolving care settings. It underscores the need for integrated evidence generation, from randomized trials to real-world studies, to support clinical decision-making and reimbursement. Through this lens, the report positions readers to understand not only what therapies exist, but how market dynamics and health-system constraints will influence clinical adoption and patient access in the near to mid term.

How therapeutic innovation, precision diagnostics, and care delivery redesign are jointly redefining treatment pathways and operational models in diabetic eye disease

The ophthalmic treatment landscape for diabetic eye disease is undergoing transformative shifts driven by therapeutic innovation, digital health integration, and evolving delivery platforms. Over the past several years, biologic agents targeting vascular endothelial growth factor and complementary pathways have redefined standard of care, while longer-acting formulations and implantable delivery systems have introduced new paradigms for treatment persistence and clinic workflow. As a result, clinicians are increasingly able to balance efficacy with reduced visit frequency, which alters how practices allocate clinical capacity and prioritize patient monitoring.

Simultaneously, diagnostic precision has improved through the adoption of advanced retinal imaging and artificial intelligence-enabled interpretation, enabling earlier detection and stratification of disease. These technology-driven advances facilitate more personalized treatment regimens and support outcome tracking across diverse care settings, from specialized ophthalmology clinics to ambulatory surgical centers. The expansion of ambulatory and outpatient procedural capacity has amplified the importance of streamlined administration formats, such as prefilled syringes and sustained-release implants, that reduce procedural complexity and improve patient throughput.

Regulatory and payer landscapes are adapting to these innovations by increasingly emphasizing real-world evidence and health economic data to assess value. Innovators and incumbents are responding with strategic partnerships, lifecycle management programs, and novel commercial models designed to demonstrate meaningful improvements in functional vision and health-related quality of life. Collectively, these forces are reshaping how therapies are developed, reimbursed, and delivered, signaling a move toward more integrated, patient-centric ophthalmic care.

Understanding the cascading operational, procurement, and strategic consequences of 2025 tariff measures on ophthalmic therapy supply chains and access

The implementation of tariffs targeting certain imported pharmaceuticals, medical devices, and related components in 2025 exerts a cumulative influence across supply chains, procurement practices, and pricing strategies in ophthalmic care. Immediate effects are seen in procurement cycles for biologic agents, implantable delivery systems, and specialized instrumentation, where increased landed costs prompt health systems and payers to reassess sourcing options. This, in turn, can create short-term disruptions in availability for high-demand therapies while incentivizing manufacturers to accelerate regional manufacturing or to reconfigure supply routes to mitigate tariff exposure.

Over time, the tariff environment encourages a strategic shift toward localized production and diversified supplier networks. Contract manufacturers and device assemblers with regional capabilities become more attractive partners, and long-term sourcing agreements are restructured to lock in more favorable terms. Clinicians and administrators may encounter changes in formulary composition as hospital purchasing groups and clinics seek alternatives that preserve clinical effectiveness while managing budget impacts. For drugs where therapeutic alternatives exist, this dynamic can prompt increased adoption of biosimilars or different delivery formats that offer cost or logistic advantages.

Crucially, tariffs also influence investment decisions for clinical development and manufacturing expansion. Companies contemplating capital deployment may prioritize investments that reduce exposure to cross-border trade vulnerabilities, such as onshore fill-finish capacity or regional packaging. From a payer and policymaker perspective, the tariff-driven landscape heightens the importance of robust health technology assessments and procurement transparency to safeguard patient access while maintaining fiscal discipline. Stakeholders who proactively adapt contracting, clinical logistics, and sourcing strategies will be better positioned to manage the operational consequences of the 2025 tariff environment.

An integrated segmentation view revealing how treatment modality, administration route, patient population, and care setting jointly determine clinical and commercial pathways

A granular segmentation analysis clarifies how treatment modalities, administration routes, patient populations, and care settings interact to influence clinical practice and commercial strategy. When treatments are considered by type, anti-VEGF therapies remain central to clinical management, with agents such as aflibercept, bevacizumab, brolucizumab, faricimab, and ranibizumab each offering distinct efficacy, dosing interval, and safety profiles that inform therapy selection. Corticosteroid options, including dexamethasone implant, fluocinolone implant, and triamcinolone, provide important alternatives for patients with inflammation-driven edema or those who respond inadequately to anti-VEGF, and their sustained-release characteristics alter monitoring cadence and clinic throughput. Laser therapy, represented by focal/grid photocoagulation and panretinal photocoagulation, continues to play a role in specific disease stages and complements pharmacologic approaches.

Route of administration is a defining commercial variable because intravitreal injection remains the predominant delivery pathway, and nuances such as the availability of prefilled syringe formats versus vial presentations affect clinic efficiency, patient comfort, and safety protocols. Systemic options delivered intravenously or orally are less common but remain relevant for particular indications and comorbidities, while topical formulations delivered as eye drops or ointments may support adjunctive care or early-stage interventions. Patient type delineation between type 1 diabetes and type 2 diabetes is clinically meaningful because disease trajectories, comorbidity profiles, and treatment engagement differ, influencing adherence patterns and follow-up needs.

End user segmentation across ambulatory surgical centers, hospitals, ophthalmology clinics, and retail pharmacies shapes how therapies are accessed and administered. Ambulatory surgical centers and specialized clinics often optimize for procedures requiring intravitreal administration or implant placement, whereas hospitals handle higher-acuity cases and complex comorbid management. Retail pharmacies play a critical role in dispensing systemic and topical therapies and are increasingly involved in patient support programs. Understanding the interplay among these segments enables stakeholders to design targeted value propositions, optimize distribution channels, and align clinical support services with the operational realities of each care setting.

Regional contrasts in infrastructure, regulatory regimes, and access priorities that decisively influence adoption pathways for diabetic ophthalmic therapies

Regional characteristics substantially influence how diabetes-related ophthalmic therapies are developed, adopted, and reimbursed, and three macro regions demonstrate distinct drivers. In the Americas, advanced clinical infrastructure, prominent specialty ophthalmology networks, and relatively well-established payer mechanisms support rapid uptake of novel biologics and sustained-release implants. However, access disparities persist across urban and rural settings, and procurement dynamics among integrated delivery networks and purchasing coalitions shape formulary decisions and therapy availability.

Europe, the Middle East, and Africa present a heterogeneous landscape where regulatory frameworks and reimbursement pathways vary significantly. In parts of Europe, centralized health technology assessment processes and strong emphasis on real-world effectiveness guide adoption, whereas markets in the Middle East and select African countries may experience more variability in availability and pricing. Across this broad region, cross-border procurement, regional manufacturing hubs, and public-private partnerships play pivotal roles in ensuring consistent access to advanced ophthalmic care.

Asia-Pacific is characterized by rapid innovation adoption in urban centers, a growing base of local manufacturers, and diverse payer models that range from national insurance schemes to out-of-pocket dominant systems. The region's large diabetic population and evolving specialty care capacity make it a focal point for clinical trials, manufacturing scale-up, and differentiated pricing strategies. Across all regions, logistical factors, regulatory timelines, and health-system priorities dictate how quickly new treatments transition from approval to routine clinical use, and regional strategies must be tailored to reflect these contextual realities.

How strategic capabilities in clinical innovation, manufacturing scale, and digital diagnostics determine competitive positioning among ophthalmic therapy stakeholders

Industry participants operating in the ophthalmic treatment ecosystem are increasingly differentiated by their ability to integrate clinical innovation with scalable manufacturing and robust commercial execution. Leading pharmaceutical and biotechnology developers that focus on biologics and long-acting agents invest heavily in clinical development programs and real-world evidence generation to demonstrate durable outcomes and support premium positioning. At the same time, manufacturers of sustained-release implants and procedural devices concentrate on improving delivery reliability and minimizing clinic burden, which enhances adoption among high-volume surgical centers and specialty practices.

Generic and biosimilar producers are strategically positioned to capture demand for lower-cost alternatives, particularly where payers prioritize cost containment. These entrants typically emphasize manufacturing efficiency, regulatory expediency, and targeted contracting to gain formulary inclusion. Meanwhile, diagnostic and digital health companies offering advanced retinal imaging or artificial intelligence tools are strengthening value propositions for early detection and treatment monitoring, thereby creating synergies with therapeutic providers seeking to demonstrate improved outcomes and optimized care pathways.

Commercial strategies among these diverse players often include partnerships with contract manufacturers, alliances with clinical networks for data generation, and coordinated patient support programs to enhance adherence. Firms that combine therapeutic differentiation with operational excellence in supply chain, regulatory navigation, and stakeholder engagement are better positioned to influence prescribing patterns and secure favorable contract terms with institutions and payers.

A pragmatic strategic playbook for stakeholders to align clinical innovation, supply resilience, and payer engagement in diabetic eye disease management

Industry leaders should pursue a multifaceted strategy that addresses clinical value, supply resilience, and payer alignment to sustain growth and improve patient outcomes. First, continuing to invest in differentiated therapeutic profiles-whether through novel molecular targets, extended-duration formulations, or delivery systems that reduce clinic visit frequency-will strengthen clinical adoption and address unmet needs in real-world practice. Parallel investment in rigorous evidence generation, including pragmatic studies and registries, is essential to demonstrate comparative effectiveness and support reimbursement dialogues.

Second, supply chain diversification and regional manufacturing partnerships will mitigate exposure to cross-border trade volatility and tariff-induced cost pressures. Establishing flexible sourcing arrangements, investing in onshore or nearshore fill-finish capabilities, and negotiating long-term contracts with critical suppliers will preserve access and stabilize procurement costs. Third, engaging payers and health systems early with transparent value propositions and outcomes-based contracting pilots can align incentives around functional vision improvements and total cost of care, increasing the likelihood of favorable formulary placement.

Finally, enhancing patient support and adherence programs, integrating digital monitoring tools, and strengthening collaborations with ambulatory surgical centers and ophthalmology clinics will optimize administration workflows and patient experience. By implementing these coordinated actions, industry leaders can navigate regulatory complexity, secure sustainable commercial pathways, and ultimately expand timely access to sight-preserving therapies for people living with diabetes.

A rigorous mixed-methods research framework combining expert interviews, clinical literature synthesis, and triangulated data validation to underpin actionable insights

This research employs a mixed-methods approach that triangulates primary qualitative insights with comprehensive secondary data to ensure robust, actionable conclusions. Primary research includes structured interviews with clinical thought leaders, hospital procurement officers, specialty clinic administrators, and payer representatives to capture operational realities, prescribing drivers, and access barriers. These stakeholder interviews are used to contextualize clinical trial evidence and to validate assumptions about care delivery dynamics and logistical constraints.

Secondary research sources include peer-reviewed clinical literature, regulatory filings, device approvals, and clinical trial registries to map therapeutic mechanisms, safety profiles, and trial endpoints. In addition, public health reports and guidelines from recognized health authorities provide the clinical practice context and inform discussions about standard-of-care approaches. Data synthesis involves cross-referencing multiple information streams to reconcile discrepancies and to derive nuanced insights about adoption barriers, administrative burden, and practical considerations for treatment deployment.

Analytical rigor is maintained through systematic data coding, thematic analysis of qualitative interviews, and iterative validation with subject-matter experts. Limitations are acknowledged, including variability in regional reporting practices and the dynamic nature of clinical development pipelines. Where gaps exist, the methodology prioritizes transparency about evidence sources and the degree of expert consensus informing key conclusions.

A concise synthesis highlighting how clinical advances, supply resilience, and stakeholder alignment will determine future access and outcomes in diabetic eye care

In summary, the management of diabetes-associated ophthalmic disease is entering a more nuanced and capability-driven phase, where therapeutic innovation, diagnostic precision, and delivery model evolution converge to reshape care pathways. Stakeholders across the value chain face the imperative of aligning product differentiation with operational feasibility, payer expectations, and patient-centered service models. As novel biologics, sustained-release technologies, and digital diagnostics mature, success will hinge on the ability to demonstrate real-world benefit while ensuring supply chain robustness and equitable access.

Operationally, the combined pressures of tariff-driven procurement shifts and the need for localized manufacturing capacity underscore the importance of proactive supply strategies. Clinically, the diversity of treatment options and administration routes requires tailored protocols that reflect patient type, comorbidity burden, and care setting capabilities. From a commercial perspective, differentiation will come from integrated offerings that link therapeutic efficacy with demonstrable improvements in care efficiency and patient experience.

For policymakers and payers, the evolving evidence base calls for adaptive assessment frameworks that value long-term functional outcomes and incentivize adherence-supporting innovations. Ultimately, a collaborative approach among manufacturers, clinicians, payers, and providers will be essential to translate technological progress into sustained reductions in vision loss attributable to diabetes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Diabetes Associated Ophthalmic Treatment Market, by Treatment Type

  • 8.1. Anti-VEGF
    • 8.1.1. Aflibercept
    • 8.1.2. Bevacizumab
    • 8.1.3. Brolucizumab
    • 8.1.4. Faricimab
    • 8.1.5. Ranibizumab
  • 8.2. Corticosteroids
    • 8.2.1. Dexamethasone Implant
    • 8.2.2. Fluocinolone Implant
    • 8.2.3. Triamcinolone
  • 8.3. Laser Therapy
    • 8.3.1. Focal/Grid Photocoagulation
    • 8.3.2. Panretinal Photocoagulation
  • 8.4. Surgical Intervention

9. Diabetes Associated Ophthalmic Treatment Market, by Route Of Administration

  • 9.1. Intravitreal Injection
    • 9.1.1. Prefilled Syringe
    • 9.1.2. Vial
  • 9.2. Systemic
    • 9.2.1. Intravenous
    • 9.2.2. Oral
  • 9.3. Topical
    • 9.3.1. Eye Drops
    • 9.3.2. Ointments

10. Diabetes Associated Ophthalmic Treatment Market, by Patient Type

  • 10.1. Type 1 Diabetes
  • 10.2. Type 2 Diabetes

11. Diabetes Associated Ophthalmic Treatment Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Ophthalmology Clinics
  • 11.4. Retail Pharmacies

12. Diabetes Associated Ophthalmic Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Diabetes Associated Ophthalmic Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Diabetes Associated Ophthalmic Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Diabetes Associated Ophthalmic Treatment Market

16. China Diabetes Associated Ophthalmic Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Adverum Biotechnologies, Inc.
  • 17.6. Aerpio Therapeutics, Inc.
  • 17.7. Alimera Sciences, Inc.
  • 17.8. Apexian Pharmaceuticals, Inc.
  • 17.9. Bayer AG
  • 17.10. Boehringer Ingelheim International GmbH
  • 17.11. F. Hoffmann-La Roche Ltd
  • 17.12. Genentech, Inc.
  • 17.13. Glycadia Pharmaceuticals, Inc.
  • 17.14. Kodiak Sciences Inc.
  • 17.15. Kubota Vision, Inc.
  • 17.16. MingSight Pharmaceuticals, Inc.
  • 17.17. Novartis AG
  • 17.18. Ocular Therapeutix, Inc.
  • 17.19. Oxurion NV
  • 17.20. Regeneron Pharmaceuticals, Inc.
  • 17.21. Regenxbio Inc.
  • 17.22. RemeGen Co., Ltd.
  • 17.23. Santen Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FARICIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FARICIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FARICIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEXAMETHASONE IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEXAMETHASONE IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEXAMETHASONE IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FLUOCINOLONE IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FLUOCINOLONE IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FLUOCINOLONE IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TRIAMCINOLONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TRIAMCINOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FOCAL/GRID PHOTOCOAGULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FOCAL/GRID PHOTOCOAGULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FOCAL/GRID PHOTOCOAGULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PANRETINAL PHOTOCOAGULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PANRETINAL PHOTOCOAGULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PANRETINAL PHOTOCOAGULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY EYE DROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY EYE DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 203. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 207. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 208. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 209. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 236. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 237. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 240. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 241. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 242. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 247. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 248. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 251. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 252. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 253. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)

TABLE 276.